​

Purple Biotech (PPBT) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

PPBT Stock Forecast

Purple Biotech stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

PPBT Analyst Ratings

Buy

According to 1 Wall Street analysts, Purple Biotech's rating consensus is 'Buy'. The analyst rating breakdown for PPBT stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Sep 19, 2024H.C. WainwrightBuyBuyHold

Purple Biotech's last stock rating was published by H.C. Wainwright on Sep 19, 2024. The company gave PPBT a "Buy" rating, the same as its previous rate.

Purple Biotech Financial Forecast

Purple Biotech Revenue Forecast

Dec 24Sep 24Jun 24
Revenue---
Avg Forecast---
High Forecast---
Low Forecast---
# Analysts---
Surprise %---

Purple Biotech's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PPBT's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Purple Biotech EBITDA Forecast

Dec 24Sep 24Jun 24
# Analysts---
EBITDA---
Avg Forecast---
High Forecast---
Low Forecast---
Surprise %---

undefined analysts predict PPBT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Purple Biotech's previous annual EBITDA (undefined) of $NaN.

Purple Biotech Net Income Forecast

Dec 24Sep 24Jun 24
# Analysts---
Net Income---
Avg Forecast$-40.72K$-207.91K$-63.32M
High Forecast$-40.72K$-207.91K$-63.32M
Low Forecast$-40.72K$-207.91K$-63.32M
Surprise %---

Purple Biotech's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PPBT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Purple Biotech SG&A Forecast

Dec 24Sep 24Jun 24
# Analysts---
SG&A---
Avg Forecast---
High Forecast---
Low Forecast---
Surprise %---

Purple Biotech's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PPBT last annual SG&A of $NaN (undefined).

Purple Biotech EPS Forecast

Dec 24Sep 24Jun 24
# Analysts---
EPS---
Avg Forecast$-0.23$-1.20$-2.30
High Forecast$-0.23$-1.20$-2.30
Low Forecast$-0.23$-1.20$-2.30
Surprise %---

According to undefined Wall Street analysts, Purple Biotech's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PPBT previous annual EPS of $NaN (undefined).

Purple Biotech Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BNOXBionomics$0.25$6.002300.00%Buy
ENLVEnlivex Therapeutics$1.19$15.001160.50%Buy
PMVPPMV Pharmaceuticals$1.50$6.00300.00%Buy
ANEBAnebulo Pharmaceuticals$1.70$6.00252.94%Buy
PPBTPurple Biotech$4.36$11.00152.29%
CVKDCadrenal Therapeutics$16.15$32.0098.14%Buy
SLNOSoleno Therapeutics$44.82$69.6755.44%Buy
SABSSAB Biotherapeutics$4.18$5.6735.65%Buy
MNPRMonopar Therapeutics$24.53$29.5020.26%Buy

PPBT Forecast FAQ

Is Purple Biotech a good buy?

Yes, according to 1 Wall Street analysts, Purple Biotech (PPBT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of PPBT's total ratings.

What are Purple Biotech's analysts' financial forecasts?

PPBT's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-63.572M (high $-63.572M, low $-63.572M), average SG&A $0 (high $0, low $0), and average EPS is $-3.735 (high $-3.735, low $-3.735).